- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Nov 18, 2023
Finance
Nov. 17 Quick Takes: WuXi XDC’s big gain in first Hong Kong trading day
Plus: Obesity play Carmot seeking NASDAQ IPO and updates from AZ, Astellas, Merck and Lilly
BioCentury | Mar 18, 2023
Finance
March 17 Quick Takes: Digital play Pear seeking alternatives
Plus: Gossamer pauses brain-penetrant Btk program, and updates from Pfizer, Astellas, Novartis and more
BioCentury | Dec 7, 2021
Market Access
Drug companies steaming about ICER report
ICER says report highlights ‘bad apples.’ Industry says it is misleading
BioCentury | May 6, 2020
Product Development
May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax
BioCentury | Nov 19, 2019
Clinical News
Big gain for Myovant as oral prostate cancer therapy heads for submission
BioCentury | Feb 15, 2019
Clinical News
Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer
BioCentury | Aug 31, 2018
Clinical News
Pfizer, Astellas speed up Phase III trials of Xtandi in hormone-sensitive prostate cancer
BioCentury | Feb 9, 2018
Clinical News
Pfizer, Astellas report detailed data for Xtandi in non-metastatic CRPC
BioCentury | Feb 5, 2018
Clinical News
Pfizer, Astellas report detailed data for Xtandi in non-metastatic CRPC
Items per page:
1 - 10 of 271